Strides Pharma Science

Stock Opportunities
41

Ok thanks and when will the delisting happen?

42

One approval from FIPB is pending and dates will come after. I think it should happen in third qtr.

43

Jefferies initiates buy rating on the stock with 1500 TP

Strides is looking to raise 1500crore

44

This is what I don’t like. I hope it remains an enabling resolution only.There is no pressing need to raise equity unless they have some grand plans to acquire something big. The debt for Australian acquisition is supposed to be manageable.

3 Likes
45

Great going! gets ANDA approved for a product having US market of USD470m with patent expired a day before on 20th Nov.

3 Likes
46

http://economictimes.indiatimes.com/markets/stocks/news/strides-arcolabs-shares-fall-as-mylan-seeks-explanation-on-agila-plant/articleshow/50179155.cms

Not sure how after a Sale this issues are dealt with

47

As far as I understand, Strides had taken a hair cut on these outstanding from Mylan mostly on these FDA observations so they would have to take confrontation route to recover anything from Strides.

48

Strides had sent this reply to BSE, on the Mylan claim news
http://www.bseindia.com/corporates/ann.aspx?scrip=532531&dur=A&expandable=0
point number 5 is the important gist out of this note

49

Religare reiterated the same defense of Strides vs Mylan and puts a target of 1570/

50

Mylan has a very arrogant leadership. I have read few interviews and it appeared that they were prodding US FDA to take appropriate regulatory actions against Indian generic manufacturers given their ‘poor’ mfg. practices.

51

Unrelated but this suspicion of FDA coming after Indian firms is gaining wider prominence. Recently, it was for DRL and yday it was for Sun. Add the H1 / L1 fee hike, all the political bonhomie seems to be going nowhere

52

Not sure how fair it is to suspect FDA and/or bilateral relationship.

I think visa fee hike has lot to do with 2016 election year in U.S.

2 Likes
53

Q3 Results

Few New Buys. Now 2nd Largest Generic company in Australia. a New CEO

54

The result they post is becoming too complex to analyse or compare. I’m invested but have switched off my mind till Q1 FY17.

55

I got tired of trying to compare and make some meaningful conclusion out of the result. Why can’t they do something simpler? I had the issue last qtr as well but this qtr, they seemed to have taken it to a new level.
PS - Sold off most of the holding y’day

56

At least the top line is good:

1514 cr (consolidated) meaning over 6000cr annualized

Exceeding expectations on topline one would say.

Disc:invested.

1 Like
57

More Acquistion

1 Like
58

I understand the reasons for acquiring these brands is that they have lots of spare capacity in their FD division. That’s why they keep mentioning “immediate earnings accretive” for every purchase.

Disc: Invested

59

See margin growing, Australian biz picking up: Strides Shasun

Read more at: http://www.moneycontrol.com/news/results-boardroom/see-margin-growing-australian-biz-picking-up-strides-shasun_6667301.html?utm_source=ref_article

60

Strides Shasun rises 4% on EIR from USFDA for Bangalore plant

Read more at: http://www.moneycontrol.com/news/buzzing-stocks/strides-shasun-rises-4eirusfda-for-bangalore-plant_6823161.html?utm_source=ref_article

Disc: Invested